Advertisement
Advertisement
Dupixent

Dupixent

dupilumab

Manufacturer:

Sanofi

Distributor:

DKSH
Concise Prescribing Info
Contents
Dupilumab
Indications/Uses
Moderate to severe atopic dermatitis in adults & ped ≥6 mth inadequately controlled or inadvisable w/ topical prescription therapies, can be used w/ or w/o topical corticosteroids. Add-on maintenance treatment for severe asthma w/ type 2 inflammation in adults & adolescents ≥12 yr. Maintenance therapy for oral corticosteroid-dependent asthma. Add-on therapy w/ intranasal corticosteroids for severe chronic rhinosinusitis w/ nasal polyposis (CRSwNP) for whom systemic corticosteroids therapy &/or surgery inadequately provide disease control. Moderate to severe prurigo nodularis (PN) in adults inadequately controlled or inadvisable w/ topical prescription therapies, can be used w/ or w/o topical corticosteroids.
Dosage/Direction for Use
SC Atopic dermatitis Adult & ped 6-17 yr, ≥60 kg Initially 600 mg, followed by 300 mg every other wk. Ped 6-17 yr, 30 to <60 kg Initially 400 mg, followed by 200 mg every other wk, 15 to <30 kg Initially 600 mg, followed by 300 mg every 4 wk. Ped 6 mth-5 yr, 15 to <30 kg 300 mg every 4 wk, 5 to <15 kg 200 mg every 4 wk. Adult & adolescent ≥12 yr Asthma Initially 400 mg, followed by 200 mg every other wk. Severe asthma, patient on oral corticosteroids or w/ severe asthma & comorbid moderate to severe atopic dermatitis or severe CRSwNP Initially 600 mg, followed by 300 mg every other wk. Adult CRSwNP 300 mg every other wk. PN Initially 600 mg, followed by 300 mg every other wk.
Contraindications
Special Precautions
Discontinue use if hypersensitivity reaction occurs. Not to be inj into tender, damaged, bruised or scarred skin. Not to be used for acute asthma symptoms or exacerbations; acute bronchospasm or status asthmaticus. Conjunctivitis, keratitis; arthralgia; comorbid asthma; parasitic helminth infections; vasculitic rash, worsened pulmonary symptoms, cardiac complications &/or neuropathy in patients w/ eosinophilia; new onset or worsening joint symptoms. Avoid abrupt discontinuation of systemic, topical or inhaled corticosteroids. Avoid use of live vaccines. Co-administration w/ non-live vaccines. Pregnancy & lactation. Ped <6 mth w/ atopic dermatitis; ped <12 yr w/ asthma; ped <18 yr w/ CRSwNP & PN.
Adverse Reactions
Inj site reactions. Atopic dermatitis, CRSwNP & PN: Conjunctivitis. Asthma & CRSwNP: Eosinophilia. Atopic dermatitis: Blepharitis, oral herpes, keratitis, eye pruritus, other HSV infection, dry eye. Asthma: Oropharyngeal pain. CRSwNP: Arthralgia, gastritis, insomnia, toothache. PN: Nasopharyngitis, herpes infection, dizziness, myalgia, diarrhea.
MIMS Class
Antiasthmatic & COPD Preparations / Nasal Decongestants & Other Nasal Preparations / Other Dermatologicals
ATC Classification
D11AH05 - dupilumab ; Belongs to the class of agents for atopic dermatitis, excluding corticosteroids. Used in the treatment of atopic dermatitis.
Presentation/Packing
Form
Dupixent soln for inj (pre-filled syringe) 200 mg/1.14 mL
Packing/Price
2 × 1's
Form
Dupixent soln for inj (pre-filled syringe) 300 mg/2 mL
Packing/Price
2 × 1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement